EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease

Tiffany Loy iD, María-Jesus Pinazo, Julio Alonso-Padilla, Jaime Altcheh, Sofia Braud-Pérez, Ivan Scandale, Marta Gómez-Burgaz, Ursula Saade, Fabiana Barreira, Natasha S Hochberg, Gerhild Angyalosi, Maan Zrein und 1 weitere

ACS Infectious Diseases · 09.10.2026

DOI: 10.1021/acsinfecdis.5c01096 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Infectious Diseases, online erschienen am 09.10.2026. Verfasst von Tiffany Loy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG , Basel4056, Switzerland. Hauptthemen laut MEDLINE: Chagas Disease, Biomarkers, Trypanosoma cruzi, Antiparasitic Agents. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas disease, caused by Trypanosoma cruzi, remains a neglected tropical disease with limited therapeutic options. Although benznidazole and nifurtimox are the available antiparasitic treatments, assessing treatment efficacy in adults with chronic Chagas disease remains challenging due to the absence of validated biomarkers or surrogate end points. Conventional serology assays often require years to decades to detect treatment-associated changes, limiting their utility in clinical trials and drug development. Biomarker development is further complicated by intermittent parasitemia, persistent antibody responses, the lack of direct measures of tissue parasite clearance, and limited longitudinal biorepositories for validation. This position paper critically evaluates biomarkers, including nonconventional serological markers such as T. cruzi 29 kDa flagellar calcium-binding protein (F29), glycosylphosphatidylinositol-anchored trypomastigote (tGPI)-mucins, and alpha-galactosyl (α-Gal) epitope; molecular approaches; and multiplex serological platforms such as MultiCruzi. Their potential utility, supporting evidence, methodological limitations, reproducibility, and validation status are assessed within a fit-for-purpose scientific and regulatory framework. Although several biomarkers have shown promise in detecting early treatment-associated biological signals, none currently has sufficient evidence to qualify as a validated surrogate end point in adult chronic Chagas disease. Early biomarker changes should therefore be interpreted as indicators of treatment-associated biological activity rather than direct evidence of parasitological cure or a durable clinical benefit. Beyond summarizing the biomarker landscape, this paper addresses the evidentiary and regulatory challenges associated with biomarker qualification and proposes a roadmap for future qualification efforts. Progress will require standardized methodologies, independent prospective validation, longer term follow-up, and robust evidence, demonstrating that biomarker changes reliably predict clinically meaningful outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chagas DiseaseBiomarkersTrypanosoma cruziAntiparasitic AgentsHumansChronic DiseaseDrug DevelopmentTrypanocidal AgentsAnimals

Stichwörter der Autor:innen

Trypanosoma cruziChagas diseaseantiparasitic agentsbiomarkersregulatory

Substanzen

BiomarkersAntiparasitic AgentsTrypanocidal Agents

Autor:innen und Institutionen

  • Novartis Pharma AG , Basel4056, Switzerland.
  • Drugs for Neglected Diseases Initiative (DNDi) , Rio de Janeiro20010-20, Brazil.
  • CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid28029, Spain.
  • Barcelona Institute for Global Health (ISGlobal) , Barcelona08036, Spain.
  • Parasitology Service, Hospital de Niños ″Ricardo Gutierrez″ and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP)-CONICET-GCBA , Buenos Aires1330, Argentina.
  • Drugs for Neglected Diseases Initiative (DNDi), Geneva1202, Switzerland.

ORCID-Profile: Tiffany Loy

Zitieren

APA

Loy, T., Pinazo, M. J., Alonso-Padilla, J., Altcheh, J., Braud-Pérez, S., Scandale, I., Gómez-Burgaz, M., Saade, U., Barreira, F., Hochberg, N. S., Angyalosi, G., Zrein, M., & Chatelain, E. (2026). A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.5c01096

Vancouver

Loy T, Pinazo MJ, Alonso-Padilla J, Altcheh J, Braud-Pérez S, Scandale I, et al. A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease. ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.5c01096

BibTeX
@article{Loy2026,
  author = {Loy, Tiffany and Pinazo, María-Jesus and Alonso-Padilla, Julio and Altcheh, Jaime and Braud-Pérez, Sofia and Scandale, Ivan and Gómez-Burgaz, Marta and Saade, Ursula and Barreira, Fabiana and Hochberg, Natasha S and Angyalosi, Gerhild and Zrein, Maan and Chatelain, Eric},
  title = {A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease},
  journal = {ACS Infectious Diseases},
  year = {2026},
  doi = {10.1021/acsinfecdis.5c01096}
}
Kostenlos starten →